Published online Nov 27, 2014. doi: 10.4254/wjh.v6.i11.800
Revised: August 27, 2014
Accepted: October 14, 2014
Published online: November 27, 2014
Core tip: In this review, we summarize the pathogenesis underlying the progression of hepatic steatosis to steatohepatitis and cirrhosis. We also discuss established drugs that are already being used to treat non-alcoholic fatty liver disease, in addition to newly discovered agents, with respect to their mechanisms of drug action, focusing mainly on hepatic insulin resistance. As well, we review clinical data that demonstrate the efficacy of these drugs, together with improvements in biochemical or histological parameters. Furthermore, we introduced future treatment option for non-alcoholic fatty liver disease.